Position in NVAX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$471
+$64 QoQ
Shares Held
50
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#245
of 263 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Gen-Wealth Partners Inc holds $1,476,128 across 15 Biotechnology names. NVAX ranks #12 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NTLA |
Intellia Therapeutics, Inc.
|
61,343 | $1,037,923 | |
| 2 | ARGX |
Argenx SE
|
230 | $213,387 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
172 | $107,248 | |
| 4 | ATNM |
Actinium Pharmaceuticals, Inc.
|
105,111 | $103,008 | |
| 5 | TNXP |
Tonix Pharmaceuticals Holding Corp.
|
533 | $6,801 | |
| 6 | QNCX |
Quince Therapeutics, Inc.
|
165 | $3,001 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
29 | $1,131 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
16 | $872 |
All Filings in NVAX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $471 | 50 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $407 | 50 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $336 | 50 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $433 | 50 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||